Review

BIOEDUSCIENCE
ISSN: 2614-1558
http://journal.uhamka.ac.id/index.php/bioeduscience

The Emergence and Impact of Artificial Intelligence in Biotechnology

Jahanzaib Ali [1*]

[1] Department of Biotechnology, Faculty of Life Sciences, University of Okara, Renala Khurd, Pakistan
[*] Correspondence: writter1008@gmail.com

Abstract

Background: Artificial intelligence (AI) has transformed many fields, including biotechnology. Artificial intelligence (AI) has been critical in altering research, drug development, genetic analysis, customized treatment, and other fields in recent years. This review article aims to investigate the numerous uses of AI in biotechnology, focusing on its impact on accelerating scientific advancement, improving data analysis, and driving innovation in the field. **Method:** Various AI approaches and methodologies used in biotechnology will be explored, including machine learning, deep learning, natural language processing, and picture identification. **Results:** This essay will also address critical problems, future potential, and ethical concerns regarding the use of AI in biotechnology. **Conclusion:** Integrating AI in biotechnology has redefined research paradigms, data analysis, and decision-making processes.

Keywords*:* Role of AI in Biotechnology; Implication of AI in Biotechnology; AI Advancements in Biological Sciences

Introduction

The integration of Artificial Intelligence (AI) technologies has revolutionized the area of biotechnology, altering research processes and enabling extraordinary discoveries. This review article aims to investigate the many uses of AI in biotechnology and their substantial impact on numerous parts of the biotechnological landscape (Oliveira, 2019).

Role of AI in Drug Discovery and Development:

Artificial intelligence (AI) has emerged as a disruptive force in drug discovery and development, disrupting established methodologies and speeding up the delivery of novel medications to the market. AI has become a powerful tool for discovering possible drug candidates, optimizing drug design, and forecasting drug toxicity due to its capacity to scan large datasets, recognize trends, and make data-driven predictions. This note investigates the significant impact of AI in drug discovery and development (Massabni & da Silva, 2019).

AI algorithms sift through massive biological and chemical datasets to identify and validate novel therapeutic targets. AI algorithms can identify specific chemicals or proteins vital to illness development by examining biological pathways, protein structures, and genetic information (Dabdoub et al., 2022). This focused method speeds up the early phases of drug discovery by concentrating research resources on promising candidates. Traditional drug screening approaches entail lengthy and costly laboratory tests. AI-driven virtual drug screening speeds up the process by simulating interactions between prospective drug candidates and target proteins. This virtual screening aids in identifying compounds with high binding affinities to the target, boosting the possibility of discovering viable therapeutic leads. AI also contributes to developing novel compounds

Check for updates

Article history
Received: 17 Aug 2023
Accepted: 02 Apr 2024
Published: 30 Apr 2024

Publisher's Note:
Bioeduscience stays neutral concerning jurisdictional claims in published maps and institutional affiliations.

Citation: Ali, J. (2024). The Emergence and Impact of Artificial Intelligence in Biotechnology. *BIOEDUSCIENCE*, *8*(1): 116-127. doi: 10.22236/jbes/12578

with desirable qualities, optimizing drug structures, and predicting drug-protein interactions (Shah et al., 2019).



Figure 1. Contributes AI to the development of novel compounds

AI in Genome Editing and CRISPR Technology

By anticipating the effectiveness and specificity of guide RNA sequences, AI algorithms help to design CRISPR targets. These algorithms examine the genomic context and off-target effects to identify guide RNA sequences that are more likely to achieve the targeted gene editing results while causing the least amount of off-target effects. AI-driven CRISPR target design has increased the success rate of gene editing experiments while decreasing the risk of unintended consequences. Using AI to analyze genome-wide CRISPR screens enables researchers to evaluate the activities of thousands of genes in parallel (Kumar & Saha, 2022). These screening methods aid in identifying genes implicated in specific biological processes, disease pathways, and medication reactions. The vast datasets generated by these screens are analyzed by AI algorithms, allowing the identification of prospective therapeutic targets and the discovery of novel gene functions. One of the most significant concerns of CRISPR technology is the possibility of off-target consequences, in which unwanted DNA sequences may be modified. AI algorithms have been created to predict and reduce off-target consequences to improve the safety and precision of CRISPR-based gene editing. Effective CRISPR component transport into target cells is essential for successful gene editing. Artificial intelligence optimizes distribution techniques, ensuring that CRISPR components reach their proper destinations efficiently and safely. With improved CRISPR delivery in vivo, AI-driven nanoparticle formulations and viral vectors are being created (Levin et al., 2020).



Figure 2. To improve CRISPR delivery in vivo, AI-driven nanoparticle formulations and viral vectors are being created.

AI-Driven Analysis of Biological Data

AI algorithms have been critical in processing large-scale sequencing data in genomics and transcriptomics. These algorithms can discover genetic variants related to diseases and phenotypic features, such as single-nucleotide polymorphisms (SNPs) and copy number variations (CNVs). AI-powered analysis also aids in the identification of gene expression patterns, alternative splicing events, and regulatory elements, offering light on gene functions and gene regulatory networks (Zare Harofte, Soltani, Siavashy, & Raahemifar, 2022). Artificial intelligence-driven analysis has substantially boosted proteomics and metabolomics research. Using machine learning methods, researchers can more correctly identify and measure proteins and metabolites in complicated samples. These studies shed light on cellular pathways, protein-protein interactions, and metabolic networks, assisting in deciphering the fundamental mechanisms of numerous biological processes. AI is accelerating the identification of promising drug candidates, revolutionizing drug discovery. Virtual screening technologies powered by AI examine massive databases of chemical compounds to anticipate their binding affinities and interactions with target proteins. This allows for the identification of lead compounds for further research (Dlamini, Francies, Hull, & Marima, 2020).

Furthermore, AI is used to anticipate medication candidates' toxicity and pharmacokinetic features, helping streamline drug development. Precision medicine has been pioneered by AI-driven analysis of patient data, including genetic, clinical, and imaging data. AI algorithms can detect illness biomarkers, allowing for earlier and more accurate disease detection. Furthermore, AI-powered predictive models aid in determining individualized treatment plans based on a patient's genetic makeup and health history, enhancing treatment outcomes. Incorporating artificial intelligence and machine learning into biological data processing has completely changed the landscape of life sciences research. AI-powered analysis enables researchers to handle large, complicated biological datasets more efficiently and accurately. AI has sped research and supported previously unattainable breakthroughs, from genetics to drug discovery and illness diagnostics. As artificial intelligence technologies progress, their potential impact on the life sciences area holds enormous promise for addressing essential concerns in human health and understanding the complexities of living systems (Melkozernov & Sorensen, 2021).

AI-Based Protein Structure Prediction

AI-based protein structure prediction has transformed structural biology by providing powerful tools for deciphering protein three-dimensional (3D) structures with unparalleled precision and speed. Understanding proteins' 3D structure is critical because it provides significant insights into their functions, interactions, and participation in numerous biological processes. Traditional protein structure determination methods, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, can be time-consuming and costly. Deep learning algorithms, in particular, have emerged as potential alternatives, considerably speeding up the protein structure prediction process (Forghani et al., 2019).

Homology modeling, often comparative modeling, is a popular AI-based protein structure prediction technique. It is based on the fact that proteins with similar sequences frequently assume identical shapes. Deep learning algorithms are used to find homologous proteins with known structures in databases, and their structures are then utilized as templates to predict the target protein's structure (Jindal, Sharma, Joshi, & Gupta, 2021). Homology modeling has improved dramatically, particularly for proteins with near homologs in the Protein Data Bank (PDB). Artificial intelligence-driven ab initio methods predict protein structures without using known templates. These methods investigate a protein's conformational space and identify the most stable 3D structure using physics-based energy functions, statistical potentials, and deep learning methodologies. Although ab initio prediction for larger proteins remains complex, advances in AI approaches have improved its accuracy and made it relevant to a broader spectrum of proteins (Harari, 2018).



Figure 3. Artificial intelligence-driven ab initio methods predict protein structures without using known templates. These methods investigate a protein's conformational space and identify the most stable 3D structure using physics-based energy functions, statistical potentials, and deep learning methodologies.

Fragment assembly approaches anticipate protein structures by combining AI algorithms with experimental or homology-based fragment libraries. Artificial intelligence-powered techniques maximize fragment pairings to produce entire 3D structures. These approaches are especially beneficial for proteins with limited database structural information. AI-based protein structure prediction has emerged as a transformational tool in structural biology, allowing for quick and precise protein structure determination. AI-driven techniques continue to evolve and offer promising solutions to long-standing issues in protein structure prediction, from homology modeling to ab initio methods and integrative modeling. The accuracy and applicability of protein structure prediction methods are expected to improve as AI technologies advance and datasets grow more extensive and diverse, opening up new opportunities for drug discovery, rational therapeutic design, and understanding the molecular basis of biological processes (Richardson et al., 2019).

Image Analysis for Disease Diagnosis and Prognosis

Image analysis is essential in disease diagnosis and prognosis, transforming medical imaging and allowing healthcare providers to make more accurate and faster decisions. Image analysis has become increasingly sophisticated as artificial intelligence and deep learning techniques have advanced, providing new insights into numerous diseases and improving patient outcomes. This article investigates the importance of image analysis in disease diagnosis and prognosis in many medical specialties (Saheb, et al., 2021). Image analysis algorithms are used in radiology to analyze a variety of medical imaging modalities, including X-rays, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). AI-powered picture analysis allows for the early detection and exact diagnosis of diseases such as cancer, cardiovascular disease, and neurological problems. Deep learning algorithms can detect tiny abnormalities, segment tumors, and quantify disease progression, allowing radiologists to make more accurate diagnoses (Harfouche et al., 2019).



Figure 4. Digital pathology platforms use AI algorithms to analyze microscopic images of tissues, detect cancerous cells, grade tumors, and predict patient outcomes

Image analysis in pathology and histology automates the study of tissue samples, improving the accuracy and efficiency of illness detection. AI algorithms are used in digital pathology platforms to examine microscopic images of tissues, detect malignant cells, grade tumors, and forecast patient outcomes. This device accelerates pathologists' productivity and allows for remote expert discussions. AI-powered image analysis is revolutionizing disease diagnosis and prognosis across multiple medical disciplines. AI-driven image analysis improves the accuracy, efficiency, and accessibility of healthcare services in fields ranging from radiology and pathology to dermatology, ophthalmology, cardiology, oncology, and neurology. Image analysis will play an increasingly important role in early disease detection, tailored treatment planning, and improving patient outcomes as AI technologies improve. However, in addition to the benefits, data protection, regulatory permission, and model validation must be addressed to enable AI's ethical and responsible use in medical imaging (Li et al., 2022).

AI for Precision Medicine in Oncology

Precision medicine in cancer is a revolutionary method that tailors medical therapy to individual patients based on their genetic makeup, lifestyle, and environmental circumstances. Precision medicine in oncology has improved dramatically by incorporating artificial intelligence, transforming cancer diagnosis, treatment choices, and patient outcomes. This article investigates the role of AI in oncology precision medicine and its potential to change cancer care. AI algorithms can mine massive volumes of genomic data to discover particular genetic abnormalities and changes that fuel cancer growth. Oncologists can recommend targeted medicines that specifically attack cancer cells while sparing healthy ones by studying the specific genomic profile of a patient's tumor. AI-powered genomic profiling enables more accurate diagnosis and treatment selection, resulting in higher patient responses and survival rates (Ji et al., 2022).

AI speeds up drug discovery by simulating and predicting the interactions between possible medications and cancer targets. Machine learning models evaluate massive databases of chemical structures, biological processes, and drug reactions to uncover novel drug candidates. AI speeds up the screening process, decreasing the time and expense of developing new cancer medicines. Furthermore, AI-driven algorithms can repurpose medications for new purposes, extending oncologists' therapeutic options. AI models can predict patient response to certain medicines based on clinical data, genomic information, and treatment history. AI assists oncologists in determining the most successful therapy for individual patients by identifying predictive biomarkers reducing the risk of ineffective treatments and associated adverse effects. This tailored strategy improves treatment outcomes while lowering unnecessary healthcare costs (Assidi, et al., 2022).



Figure 5. By leveraging the vast amounts of data available in the era of big data and genomics, AI algorithms enable personalized treatment plans that are tailored to each patient's unique cancer profile

AI has become a potent tool in oncology precision medicine, transforming cancer care from diagnosis to treatment selection and patient monitoring. AI algorithms provide personalized treatment strategies tailored to each patient's specific cancer profile by harnessing the massive volumes of data accessible in the era of big data and genomics. As AI advances, its ability to change precision medicine in oncology offers great promise for improving patient outcomes and altering the cancer care environment. However, to fully utilize AI's benefits in precision oncology, issues such as data privacy, regulatory compliance, and clinical practice integration must be addressed (Riordon et al., 2019).

AI and Next-Generation Sequencing:

Artificial intelligence (AI) and next-generation sequencing (NGS) are two cutting-edge technologies that have revolutionized genetics and biomedical research. NGS, also known as high-throughput sequencing, enables the quick and low-cost sequencing of DNA and RNA molecules. Conversely, AI has the potential to analyze and interpret large-scale genetic data with unparalleled speed and precision, thanks to machine learning and deep learning algorithms. This paper investigates the synergistic link between AI and NGS and the implications for genome research, customized medicine, and other applications. Massive volumes of genetic data are generated by NGS, which might be daunting to evaluate manually. AI algorithms, particularly machine learning models, can quickly process and analyze this massive data, detecting genetic variations, mutations, and probable disease-causing genes. AI-powered systems can swiftly annotate and prioritize genomic variants, decreasing data interpretation time and expediting genomic research (Johnson, et al., 2022).

AI and NGS have significantly advanced precision medicine approaches. AI algorithms can analyze individual patient genetic data to find specific mutations or biomarkers that may influence illness risk and drug response. With this individualized approach, oncologists can adapt treatment tactics, selecting treatments most likely helpful for a particular patient's genetic profile. NGS generates raw sequencing data, and finding significant genomic variations from this data is a vital step in genomics research. AI-based variant calling algorithms can detect genetic mutations and structural differences more accurately, increasing the sensitivity and specificity of variant identification. Furthermore, AI can help with variant interpretation by cross-referencing massive genomic databases and literature, providing valuable insights into the possible clinical importance of detected variants (Johnson et al., 2022).

AI and NGS have transformed cancer genomics, allowing new cancer biomarkers and therapeutic targets to be discovered. AI algorithms can mine tumor genomic data for driver mutations and atypical pathways that lead to cancer growth and progression. This data aids in developing targeted treatments and individualized treatment regimens for cancer patients. Deep learning and other AI-driven algorithms help interpret gene expression data obtained by NGS technology. These algorithms can decipher complex gene regulation networks, detect co-expression patterns, and predict gene function. AI supports integrating multi-omics data (genomics, transcriptomics, proteomics, and so on), allowing for a comprehensive understanding of biological processes and disease mechanisms (Melkozernov & Sorensen, 2021).



Figure 6. Integrating AI and next-generation sequencing has revolutionized genomics research, personalized medicine, and drug development. AI's ability to process and analyze vast amounts of genomic data has accelerated the pace of discovery.

Artificial intelligence and next-generation sequencing have transformed genomics research, personalized medicine, and medication discovery. The ability of artificial intelligence (AI) to handle and analyze massive volumes of genomic data has expedited the speed of discovery, allowing researchers and clinicians to make groundbreaking advances in understanding disease mechanisms, discovering therapeutic targets, and personalizing treatments to specific patients. As AI and NGS technologies evolve, their combined ability to drive precision medicine, unravel the complexity of the human genome, and enhance patient outcomes will only grow, ushering in a new era of genomics-driven healthcare. To fully utilize the benefits of AI and NGS in clinical practice, however, problems relating to data protection, standardization, and interpretability must be addressed (Jindal et al., 2021).

AI in Stem Cell Therapies

AI has emerged as a transformational tool in various medical sectors, including stem cell therapy. Stem cell therapies, which harness the regenerative potential of stem cells, show enormous promise for treating a wide range of diseases and injuries. However, the effectiveness of these therapies depends on some crucial aspects, including identifying and characterizing appropriate stem cell populations, efficient differentiation processes, and tailored treatment techniques. Large databases of stem cell features, such as gene expression profiles, cell surface markers, and epigenetic signatures, can be analyzed by AI algorithms to identify specific subpopulations of stem cells with desired qualities. AI-powered image analysis techniques also allow for the automatic and accurate assessment of stem cell morphology and viability, ensuring the selection of high-quality stem cell populations for transplantation (Harari, 2018).



Figure 7. Stem cell differentiation is a critical step in regenerative medicine, where stem cells are guided to mature into specific cell types. AI-driven predictive models analyze vast amounts of omics data and experimental results to optimize differentiation protocols.

In regenerative medicine, stem cell differentiation is a vital stage in which stem cells are led to mature into specific cell types. AI-driven predictive models examine massive volumes of omics data and experimental findings to optimize differentiation processes. These models can anticipate the most efficient and reproducible conditions for differentiating stem cells into distinct cell lineages, thereby speeding up the development of cell-based therapeutics. Artificial intelligence technology, such as robots and process automation, is essential in streamlining stem cell manufacturing operations. Automated systems promote consistent stem cell generation, decreasing manual errors and batch-to-batch variability. This efficiency is critical for large-scale stem cell manufacturing required for clinical applications. AI-powered imaging and tracking algorithms can track the fate of implanted stem cells in vivo. Non-invasive imaging tools, such as bioluminescence and magnetic resonance imaging (MRI), combined with AI analysis, let researchers analyze the survival, migration, and integration of transplanted stem cells over time, assisting in the optimization of treatment procedures (Kumar & Saha, 2022).

The incorporation of AI in stem cell therapies has transformed the area of regenerative medicine, expanding our understanding of stem cell biology and creating effective treatments for various diseases and injuries. Artificial intelligence-powered technologies have the potential to speed up stem cell research, improve stem cell-based therapeutics, and pave the road for individualized regenerative medicine. As AI advances, its synergy with stem cell technology will create new paths for translating stem cell research from the laboratory to the clinic, providing promise for improved patient outcomes and dramatic developments in healthcare. To ensure the safe and responsible use of AI in stem cell therapies, it is critical to solve difficulties relating to data privacy, regulatory compliance, and ethical considerations. Collaboration between researchers, doctors, and regulatory authorities will be essential in realizing AI's full potential in improving stem cell-based therapeutics (Kumar & Saha, 2022).

Challenges and Limitations of AI in Biotechnology:

While AI has demonstrated significant potential in various areas of biotechnology, it is essential to acknowledge the challenges and limitations accompanying its implementation. Some of the key challenges include:

Data Quality and Availability:

AI systems rely substantially on huge and high-quality datasets for training and validation. However, getting comprehensive and well-annotated datasets in biotechnology can be difficult due to the complexity and diversity of biological systems. Furthermore, providing sensitive patient data for research can cause privacy concerns, resulting in limitations in data availability.

Interpretability and Explain-ability

Deep learning models, such as neural networks, frequently operate as black boxes, making it challenging to explain their conclusions and comprehend the logic underlying their predictions. Lack of explainability can significantly hinder regulatory approval and user trust in essential applications such as drug research and healthcare.

Biological Complexity

Biological systems are complex and dynamic by nature, with numerous variables and linkages. AI algorithms may struggle to adequately capture the complicated interactions between biological components. Overfitting and bias in AI systems might result in incorrect predictions and impede outcomes' generalizability.

Lack of Standardization

Diverse research groups and companies may use diverse AI approaches in biotechnology, resulting in inconsistent methodologies and findings. This can make comparing findings and reproducing experiments difficult, lowering the reliability of AI-driven outcomes.

Computational Resources

Implementing AI in biotechnology frequently necessitates considerable computational resources and expertise. Advanced AI models are intense learning models that require expensive technology and significant training time. Some scholars and universities may find this prohibitively expensive.

Regulatory and Ethical Considerations

Using AI in medical applications and drug development poses ethical and regulatory concerns about patient safety, data privacy, and prejudice. Regulatory agencies may need to modify their standards to meet the unique issues provided by AI in biotechnology.

Bias and Generalization

If not appropriately addressed, biased data used to train AI algorithms might result in skewed predictions and increase health inequities. Furthermore, AI models that perform well in one biological setting may not perform well in another, necessitating thorough validation and adaptation.

Human Expertise and Collaboration

AI technologies should supplement human skills rather than replace them. Collaboration between AI professionals, biologists, physicians, and other stakeholders is critical to ensuring the successful integration of AI in biotechnology and realizing its full potential.

Security and Privacy Concerns:

In biotechnology, AI frequently entails handling sensitive information and proprietary data. To prevent data breaches and illegal access, it is vital to implement strong cybersecurity measures and protect intellectual property rights.

Conclusions

Incorporating artificial intelligence in biotechnology has reshaped research paradigms, data analysis, and decision-making processes. The impact of AI on drug discovery, genomics, bioinformatics, high-throughput screening, medical imaging, and next-generation sequencing is highlighted in this review article. However, difficulties such as data quality, ethical considerations, and integration issues must be solved to realize AI's potential in biotechnology fully. AI is poised further to change biotechnology with ongoing developments and emerging trends, paving the way for groundbreaking discoveries and tailored therapeutic interventions. While ethical concerns must be addressed, the advantages of using AI in biotechnology far exceed the drawbacks. We should expect even more significant breakthroughs in the industry with continuing study and development. We encourage you to continue studying this intriguing research area and stay current on the newest advances in AI and biotechnology.

Declaration statement

The authors reported no potential conflict of interest.

References

Assidi, Mourad, Buhmeida, Abdelbaset, & Budowle, Bruce. (2022). Medicine And Health Of 21st Century: Not Just A High Biotech-Driven Solution. *Npj Genomic Medicine, 7*(1), 67. Https://Doi.Org/10.1038%2Fs41525-022-00336-7

Dabdoub, Fatema, Colangelo, Margaretta, & Aljumah, M. (2022). Artificial Intelligence In Healthcare And Biotechnology: A Review Of The Saudi Experience. *Journal Artif Intell Cloud Comput, 107*, 2-6. https://doi.org/10.47363/JAICC/2022(1)107

Dlamini, Z., Francies, Flavia Zita, Hull, R., & Marima, Rahaba. (2020). Artificial Intelligence (AI) And Big Data In Cancer And Precision Oncology. *Computational and structural biotechnology journal, 18*, 2300-2311. https://doi.org/10.1016/j.csbj.2020.08.019

Forghani, Reza, Savadjiev, P., Chatterjee, A., Muthukrishnan, N., Reinhold, C., & Forghani, Behzad. (2019). Radiomics and Artificial Intelligence For Biomarker And Prediction Model Development In Oncology. *Computational and structural biotechnology journal, 17*, 995. https://doi.org/10.1016%2Fj.csbj.2019.07.001

Harari, Y. Noah. (2018). Why technology favors tyranny. *The Atlantic, 322*(3), 64-73.

Harfouche, Antoine L, Jacobson, Daniel A, Kainer, David, Romero, Jonathon C, Harfouche, Antoine H, Mugnozza, Giuseppe Scarascia, Altman, Arie. (2019). Accelerating Climate Resilient Plant Breeding By Applying Next-Generation Artificial Intelligence. *Trends in biotechnology, 37*(11), 1217-1235. https://doi.org/10.1016/j.tibtech.2019.05.007

Ji, Li, Paul, Puja, Shanbhag, Bhuvana K, Dixon, Ian, Kuang, Shibo, & He, Lizhong. (2022). Emerging Application Of Hydrocyclone In Biotechnology And Food Processing. *Separation and Purification Technology*, 122992. https://doi.org/10.1016/j.seppur.2022.122992

Jindal, S., Sharma, A., Joshi, A., & Gupta, Muskan. (2021). *Artificial Intelligence Fuelling The Health Care.* Paper presented at the Mobile Radio Communications and 5G Networks: Proceedings of MRCN 2020.

Johnson, Prince Chacko, Laurell, Christofer, Ots, Mart, & Sandström, Christian. (2022). Digital Innovation And The Effects Of Artificial Intelligence On Firms' Research And Development–Automation Or Augmentation, Exploration Or Exploitation? *Technological Forecasting and Social Change, 179*, 121636. https://doi.org/10.1016/j.techfore.2022.121636

Kumar, R., & Saha, Purabi. (2022). A Review On Artificial Intelligence And Machine Learning To Improve Cancer Management And Drug Discovery. *International Journal for Research in Applied Sciences and Biotechnology, 9*(3), 149-156. https:/doi.org/10.31033/ijrasb.9.3.26

Levin, Jeremy M, Oprea, Tudor I, Davidovich, Sagie, Clozel, Thomas, Overington, John P, Vanhaelen, Quentin, . . . Zhavoronkov, Alex. (2020). Artificial Intelligence, Drug Repurposing And Peer Review. *Nature Biotechnology, 38*(10), 1127-1131. https://doi.org/10.1038/s41587-020-0686-x

Li, Haining, Chiang, Austin W., & Lewis, Nathan E. (2022). Artificial Intelligence In The Analysis Of Glycosylation Data. *Biotechnology Advances, 60*, 108008. https://doi.org/10.1016/j.biotechadv.2022.108008

Massabni, Antonio Carlos, & da Silva, Gilson José. (2019). Biotechnology And Industry 4.0: The Professionals Of The Future. *International Journal of Advances in Medical Biotechnology-IJAMB, 2*(2), 45-53. https://doi.org//10.25061/2595-3931/IJAMB/2019.v2i2.39.

Melkozernov, Alexander N, & Sorensen, Vibeke. (2021). What Drives Bio-Art In The Twenty-First Century? Sources Of Innovations And Cultural Implications In Bio-Art/Biodesign And Biotechnology. *AI & SOCIETY, 36*, 1313-1321. https://doi.org//10.1007/s00146-020-00940-0

Oliveira, Arlindo L. (2019). Biotechnology, Big Data And Artificial Intelligence. *Biotechnology Journal, 14*(8), 1800613. https://doi.org/10.1002/biot.201800613

Richardson, L. C, Connell, Nancy D, Lewis, Stephen M, Pauwels, Eleonore, & Murch, Randy S. (2019). Cyberbiosecurity: A Call For Cooperation In A New Threat Landscape. *Frontiers In Bioengineering And Biotechnology, 7*, 451363. https://doi.org/10.3389/fbioe.2019.00099

Riordon, J., Sovilj, Dušan, Sanner, Scott, Sinton, David, & Young, Edmond WK. (2019). Deep Learning With Microfluidics For Biotechnology. *Trends In Biotechnology, 37*(3), 310-324. https://doi.org/10.1016/j.tibtech.2018.08.005

Saheb, Tahereh, Saheb, Tayebeh, & Carpenter, David O. (2021). Mapping Research Strands Of Ethics Of Artificial Intelligence In Healthcare: A Bibliometric And Content Analysis. *Computers in Biology and Medicine, 135*, 104660. https://doi.org/10.1016/j.compbiomed.2021.104660

Shah, Pratik, Kendall, Francis, Khozin, Sean, Goosen, Ryan, Hu, J., Laramie, J.,nSchork, N. (2019). Artificial Intelligence And Machine Learning In Clinical Development: A Translational Perspective. *NPJ digital medicine, 2*(1), 69. https://doi.org/10.1038/s41746-019-0148-3

Zare Harofte, Samaneh, Soltani, Madjid, Siavashy, Saeed, & Raahemifar, Kaamran. (2022). Recent Advances Of Utilizing Artificial Intelligence In Lab On A Chip For Diagnosis And Treatment. *Small, 18*(42), 2203169. https://doi.org/10.1002/smll.202203169